{
    "organizations": [],
    "uuid": "6108a1fdd20956d45315136ec54af299cb2207a9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-geneuro-fy-net-loss-for-the-period/brief-geneuro-fy-net-loss-for-the-period-narrows-to-5-8-million-euros-idUSFWN1RG0SK",
    "ord_in_thread": 0,
    "title": "BRIEF-Geneuro FY Net Loss For The Period Narrows To 5.8 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - GENEURO SA:\n* FY NET LOSS FOR THE PERIOD EUR 5.8 MILLION VERSUS LOSS OF EUR 14.1 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 5.7 MILLION VERSUS LOSS OF EUR 14.0 MILLION YEAR AGO\n* CASH POSITION AT DEC 31 WAS EUR 26.6 MILLION * TOP-LINE RESULTS FROM PHASE IIA TYPE 1 DIABETES TRIAL EXPECTED END Q3 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-04T00:23:00.000+03:00",
    "crawled": "2018-04-04T12:33:15.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "geneuro",
        "sa",
        "fy",
        "net",
        "loss",
        "period",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "cash",
        "position",
        "dec",
        "eur",
        "million",
        "result",
        "phase",
        "iia",
        "type",
        "diabetes",
        "trial",
        "expected",
        "end",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}